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New horizons from novel therapies in malignant pleural 
mesothelioma
Abstract 
Malignant pleural mesothelioma (MPM) is a relatively rare, but highly lethal cancer of the pleural mesothelial cells. Its pathoge-
nesis is integrally linked to asbestos exposure. In spite of recent developments providing a more detailed understanding of the 
pathogenesis, the outcomes continue to be poor. To date, trimodality therapy involving surgery coupled with chemotherapy and/
or radiotherapy remains the standard of therapy. The development of resistance of the tumor cells to radiation and several che-
motherapeutic agents poses even greater challenges in the management of this cancer. Ionizing radiation damages cancer cell 
DNA and aids in therapeutic response, but it also activates cell survival signaling pathways that helps the tumor cells to overcome 
radiation-induced cytotoxicity. A careful evaluation of the biology involved in mesothelioma with an emphasis on the workings of 
pro-survival signaling pathways might offer some guidance for treatment options. This review focuses on the existing treatment 
options for MPM, novel treatment approaches based on recent studies combining the use of inhibitors which target different 
pro-survival pathways, and radiotherapy to optimize treatment.
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Introduction
Malignant pleural mesothelioma (MPM) 
is a rare and aggressive cancer with a reported 
worldwide incidence of only 10 to 30 cases per 
million [1]. This malignancy involves the meso-
thelial cells of the pleura and its pathogenesis 
is attributed to a direct causal relationship with 
prolonged exposure to airborne asbestos particles. 
Chronic exposure to asbestos leads to inflamma-
tory changes in the pleural mesothelium, sub-
sequently leading to malignant transformation 
[2]. The most common sub-type of MPM is the 
epithelioid variety, followed by the sarcomatous 
and biphasic types [3]. 
The current standard treatment strategies 
for MPM include surgery for resectable tumors 
in combination with radiotherapy (RT) and che-
motherapy. In spite of recent advances and rese-
arch focused towards novel approaches to manage 
MPM, the median survival of patients with MPM 
is still estimated to be 8 to 14 months [4]. With the 
emerging resistance of the MPM tumor cells to RT 
and chemotherapy, there is an even greater need 
for developing new treatment approaches which 
can bypass and overcome these obstacles. Cancer 
immunotherapy has shown tremendous promise 
in providing solutions which can aid in improving 
the poor outcomes that continue to be associated 
with MPM. A more detailed understanding of 
the molecular biological mechanisms in MPM 
has provided hope that novel combinations of 
targeted therapies along with administration of ra-
diation can be successfully developed to enhance 
the immune response against this malignancy. In 
view of this, we evaluate the available treatment 
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modalities for MPM, with a particular emphasis 
placed on the various cell survival pathways and 
the latest developments in the field of targeted 
chemotherapy and immunotherapy.  
Current treatment approaches in MPM
The trimodality treatment involving surge-
ry in combination with chemotherapy and/or 
radiotherapy continues to be the standard ap-
proach for management of MPM. Being an 
important and common treatment option in 
the treatment of MPM, surgery has been em-
ployed to either potentially cure the cancer or 
to provide palliation. The two main surgical 
methods include extra-pleural pneumonectomy 
(EPP) and pleurectomy with decortication (P/D). 
The preferred surgical of MPM continues to be 
widely debated with several studies showing 
conflicting results. Some retrospective studies 
have favored extended P/D, because it shows 
lower peri-operative mortality, morbidity, lower 
post-operative complications and better survival 
when compared to EPP (5, 6). Owing to the lack 
of randomized control trials, a clear conclusion 
of the optimal surgical procedure cannot yet be 
clearly determined. The National Comprehensi-
ve Cancer Network (NCCN) guidelines for MPM 
suggest that P/D is considered safer to EPP due 
to less post-operative complications and a higher 
quality of life. 
RT is employed as an adjuvant or neoadju-
vant treatment option in MPM and is mainly 
considered a palliative option [7]. Intensity mo-
dulated proton therapy has been suggested as 
a feasible option in the management of MPM in 
a recent study involving 7 patients [8]. Volume-
tric modulated arc therapy, a rotational form of 
intensity-modulated RT has also been conside-
red in management of MPM [9]. Chemotherapy 
is considered a part of the trimodality regimen 
for MPM in patients, either before or after sur-
gery and has shown to provide a median OS of 
24 months [10]. In patients who refuse surgery 
and in medically inoperable patients, chemothe-
rapy alone can also be considered [11]. The 
first-line treatment for MPM includes a combi-
nation of pemetrexed and cisplatin. Based on 
a recent study by Zalcman et al., the NCCN guide-
lines recommended addition of bevacizumab to 
cisplatin-pemetrexed regimen for patients with 
unresectable MPM [12]. Pemetrexed-carboplatin 
and gemcitabine-cisplatin have also been recom-
mended as acceptable first-line regimens based 
on relevant recent studies [13, 14].
Induction of cell survival pathways
Epidermal growth factor receptor (EGFR) 
pathway
EGFR is a transmembrane glycoprotein which 
belongs to the Her1 group of the ErbB family of 
tyrosine kinases [15]. This receptor forms an in-
tegral part of a complex signaling cascade which 
plays an important role in physiological pathways 
including controlling cell growth, proliferation and 
survival. Ligand binding to EGFR, phosphorylation 
of tyrosine residues, followed by receptor dimeriza-
tion are the three steps which lead to cellular proli-
feration [16]. The overexpression of these receptors 
has been deemed significant in the pathogenesis 
of several cancers, which has led to the focus on 
development of targeted therapies towards these 
receptors [17]. Overexpression of EGFR is noted 
in about 70% of tissue specimens of MPM [18]. 
Asbestos, which is the major carcinogen associated 
with MPM, triggers aggregation of EGFR by forming 
reactive oxygen species, resulting in autophospho-
rylation and EGFR activation. This is subsequently 
followed by activation of the RAS/RAF/MAPK 
pathway leading to cellular proliferation and me-
tastasis [19, 20]. There are several studies which 
have focused on EGFR gene mutations involved in 
MPM over the last few years. A study conducted 
in Japan demonstrated the presence of missense 
mutations of the EGFR gene in some cases of MPM 
[21]. Recent studies have suggested an epigenetic 
component involved in development of MPM. 
Moreover, oncogenic EGFR gene has been shown 
to cause downregulation and repression of Ten-ele-
ven translocation enzymes (TET) DNA methylase, 
which leads to silencing of tumor suppressors [22].
The effect of radiation on the proliferation of 
tumor cells and association with EGFR has been 
studied extensively. The amplification of cellular 
proliferation after exposure to ionizing radiation 
is termed as accelerated repopulation and has 
been shown to be contributing partly to the de-
velopment of radioresistance, especially in head 
and neck malignancies [23]. The possible mecha-
nisms of EGFR phosphorylation and subsequent 
activation by radiation has been attributed to the 
release of TGF-alpha, which is an EGFR binding 
ligand [24]. A study detailing the effects of the 
combination of RT with ZD1839 (Iressa), which 
is a selective EGFR inhibitor in several cancers 
including mesotheliomas, conclusively showed 
that the combination arm yielded significant 
improvements in therapeutic index for radiation 
and enhanced tumor suppression compared to 
the radiation alone arm [25].
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The two classes of drugs with established 
anti-EGFR targeted action are tyrosine kinase 
inhibitors (TKI) and monoclonal antibodies. TKIs 
such as gefitinib, afatinib, erlotinib, canertinib 
and lapertinib impart their action by acting as 
ATP analogues, competitively inhibiting the 
catalytic tyrosine kinase domain intracellularly. 
In-vitro studies have demonstrated that small 
molecule TKIs effectively decrease MPM cell 
proliferation [26]. However, initial clinical trials 
involving gefitinib showed no clinical efficacy in 
patients with MPM [27]. This contrast has been 
attributed to the theory that TKIs exert their ac-
tion only in the presence of activating mutations 
of the EGFR gene, which are very rarely seen in 
MPM. As very few patients carry these mutations, 
the clinical efficacy of these drugs, when given 
individually, is lacking [28]. A Japanese study 
has been conducted in a patient harboring a rare 
EGFR mutation of G719C and S768I had been 
successfully treated with afatinib [29].
Monoclonal antibodies against the extra-
cellular portion of EGFR such as cetuximab, 
nimotuzumab and panitumumab act by creating 
ligand inhibition, thereby blocking receptor di-
merization and further downstream signaling. 
They also cause internalization and degradation 
of EGFR receptors leading to further downregu-
lation [30]. The use of cetuximab, a chimeric 
mouse-human antibody, in rodent models has 
demonstrated significant tumor inhibition and 
improved survival [31]. Another monoclonal 
antibody, Nimotuzumab, approved for the treat-
ment of colorectal and head and neck cancers, 
has demonstrated significant reduction in tumor 
volumes when compared to cisplatin-gemcitabine 
chemotherapy in animal models [32]. Novel EGFR 
targeted nanotechnology delivery techniques 
such as TargomiRs which are targeted minicells 
which are loaded with miR-16 mimic microRNA 
have also shown promise in preclinical models 
and clinical trials [33, 34].
Extracellular signal-regulated kinase 
(ERK) pathway
Mitogen-activated protein kinase (MAPK) 
pathway, which forms an integral link between 
upstream extracellular stimuli and downstream 
intracellular effectors, regulates cell differentia-
tion, proliferation and death in both physiologi-
cal and pathological milieus [35]. This cascade, 
which has been identified to be the most frequ-
ently mutated signaling pathway in humans, is 
composed of a RAS-RAF-MEK-ERK chain. Two 
types of distinct ERK proteins, ERK1 and ERK2, 
are activated by MEK through phosphorylation of 
their tyrosine and threonine residues, which re-
sults in the activation of transcription factors and 
kinases which predominantly orchestrates cellu-
lar proliferation. Activation of several feedback 
loops between substrates and ERK further am-
plifies cell differentiation [36]. The significance 
of ERK has been clearly demonstrated in studies 
related to epithelioid type of MPM. ERK2 was 
conclusively shown to be critical in the trans-
formation and homeostasis of mesotheliomas by 
controlling gene expression in animal studies 
[37]. An in-depth analysis of asbestos-induced 
signaling pathways also reiterated the impor-
tance of ERK in the development of malignant 
mesothelioma. The transcription factor activator 
protein-1 controls proliferation of mesothelial 
cells by elevation of ERK-dependent Fos-related 
antigen (Fra)-1 [38]. Thus, downstream ERK, 
which controls a critical juncture in this pathway, 
has been targeted as a potential opportunity for 
treatment of cancers, especially those with MEK, 
RAF and RAS mutations. 
Radiation leads to activation of the ERK 
pathway by causing tyrosine and threonine pho-
sphorylation of ERK1 and ERK2 by MEK, which 
prolongs cell survival and proliferation [39]. This 
activation of ERK by radiation leads to expression 
of anti-apoptotic proteins such as Mcl-1, and 
Bcl-xL [40]. It also inhibits some pro-apoptotic 
proteins such as caspase 9 and Bim, leading to 
the inhibition of tumor cell suppression [41]. 
A link between radioresistance and ERK5 has 
been established in a study by Jiang et al. which 
showed that ERK5 overactivation was noted in 
lung cancer development and G2/M cycle trans-
mission. ERK5 was also identified as a potential 
regulator of radiosensitivity in cancer cells and 
supported its use as a biomarker to predict radio-
sensitivity [42]. 
In therapeutic targeting of the MAPK pa-
thway, the initial design and development of 
newer drugs was focused on RAF and MEK 
proteins. The inevitable drug resistance that 
develops against RAF and MEK inhibitors has 
shifted the focus to novel ERK inhibitors. Use 
of a specific ERK5 inhibitor XMD8-92 in human 
MPM cells conclusively showed inhibition of 
ERK5 phosphorylation, which eventually led to 
attenuation of MPM tumor growth by an inflam-
masome-mediated mechanism [43]. A recent 
study demonstrated that zoledronic acid can po-
tentially aid in restoring immune reactivity and 
chemosensitivity in MPM by decreasing RAS/ERK 
activity [44]. A single-arm clinical trial carried 
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out in 8 patients with advanced MPM showed 
modest clinical activity and no significant toxic 
effects in patients who received zoledronic acid 
[45]. An in vivo microenvironment study showed 
that Pirfenidone can decrease proliferation and 
migration of MPM cells by causing inhibition of 
ERK [46]. Arsenic trioxide (ATO), an inorganic 
compound used in traditional Chinese medicine, 
has been shown to induce apoptosis in MPM cell 
lines by affecting MAPK pathways such as ERK 
and c-Jun NH2-terminal kinase pathway [47]. 
In addition to these mechanisms, ATO has also 
demonstrated apoptosis in MPM cell lines by do-
wnregulating thymidylate synthase, Gli1 expres-
sion and E2F1 transcription factor [48, 49]. The 
potential benefits of these agents in all these 
studies provides a possible option in the future 
for repurposing them for use in MPM patients. 
cAMP response element binding protein 
(CREB)
CREB, which belongs to the group of basic 
leucine zipper (bZIP) containing transcription 
factors, is a major regulator of basic cellular 
homeostasis, differentiation and growth [50]. 
After undergoing phosphorylation at its serine 
residues by other kinases, the transcriptional ac-
tivity of CREB is activated [51]. Subsequently by 
regulating histone H3 and H4 methylation which 
controls chromatin recruitment, CREB modulates 
a number of physiological processes such as cell 
cycle, DNA repair, cell proliferation, angiogene-
sis, inflammation and immune responses [52, 53]. 
Overexpression of CREB has been implicated in 
many cancers such as glioblastoma, non-small 
cell lung carcinoma, breast carcinoma, hematopo-
ietic malignancies and malignant mesothelioma, 
to name a few [54, 55]. CREB overexpression has 
also been shown to correlate with tumor recur-
rences, poorer prognoses and reduced survival 
in tumor patients [56, 57]. Several studies have 
emphasized the role of CREB in the pathogenesis 
of malignant mesothelioma. An in vitro study 
conducted on MPM cells showed that asbestos 
induced apoptosis also triggered the expression 
of several CREB target genes. It also demonstrated 
that doxorubicin increased the phosphorylation 
of CREB1 [58]. Another study using genetical-
ly CREB-silenced MPM cell lines and mouse 
xenograft models, conclusively proved that by 
regulating inflammatory signals, CREB plays 
a major role in controlling MPM tumor growth 
and development [59].
The activation of CREB following induction 
with radiation has been linked to radiosensiti-
vity in several studies.  A study by D’Auria et 
al. suggested that low dose radiation can trigger 
activation of CREB leading to cell survival. It also 
reviewed the pro-apoptotic role of CREB after 
exposure to ionizing radiation. This suggests that 
multiple mechanisms are involved in the radia-
tion-CREB interaction and that future clinical 
trials involving this combination can provide 
a solution in cancer treatment [60]. Another study 
by Cataldi et al. showed that activation of CREB 
improves signal in leukemia cells which were 
exposed to ionizing radiation [61].
KG-501, a CREB inhibitor has been identi-
fied which can reversibly inhibit the interaction 
between CREB and CBP (CREB binding protein). 
The use of vandetanib, a tyrosine kinase inhibi-
tor, along with doxorubicin in human MPM lines 
demonstrated that vandetanib alone decreased 
cell numbers in epithelioid cell lines and when 
used together synergistically resulted in increased 
doxorubicin toxicity in both epithelioid and sar-
comatous cell lines [62]. This study suggested the 
combined use of these two drugs as a potential 
treatment option for MPM, owing to the impact 
on both ERK5 and CREB pathways. A new agent 
666-15 has been identified as a CREB inhibitor
with significant anti-tumor effects noted in both
in vivo and in vitro studies and it holds promise
as a future therapeutic option for MPM [63, 64].
Protein kinase B (AKT)
AKT is a serine/threonine kinase which 
exists as 3 isoforms and controls many cellular 
activities such as glucose metabolism, cell cycle 
progression and protein synthesis. It also blocks 
apoptosis by causing inactivation of several pro-a-
poptotic proteins [65, 66]. After being activated 
by phosphorylation, AKT induces a number 
of proteins located in the nucleus, cytosol and 
plasma membrane such as PRAS40, vimentin, 
palladin, p21 and p27 which enhance metasta-
tic proliferation of cells [67, 68]. The system 
located upstream of AKT generates phosphati-
dylinositol triphosphate (PIP3) with the action of 
phosphoinositide 3-kinase (PI3K) [69]. AKT over 
activation has been commonly noted in several 
human malignancies including ovarian carci-
noma, gastric carcinoma and pancreatic cancer 
[70]. Some proteins in the AKT pathway such as 
PI3K, periostin, eIF4E function as oncoproteins 
when they are overexpressed. On the other hand, 
inactivation of tumor suppressor genes in the AKT 
pathway such as PTEN, TSC and FOXO leads 
towards malignancy causing paths, with PTEN 
mutations being the highest frequency [71, 72]. 
Mutlay Sayan et al., Novel therapies for mesothelioma
5www.journals.viamedica.pl
The role of radiation on AKT pathway has 
been analyzed in many studies. Li et al. conclusi-
vely proved in a study involving 8 cell lines of 
glioblastoma multiforme that induction of AKT 
activation by ionizing radiation led to an incre-
ase in radioresistance of the cancer cells. They 
showed that a serum factor may be involved and 
EGFR inhibition by AG1478 and PI3K inhibition 
with LY294002 can help increase radiosensitivity 
in tumor cells [73]. Toulany et al. pointed out that 
understanding the specific dysregulations of AKT 
such as gene amplification, point mutations and 
overexpression, which eventually lead to AKT 
activation might result in a clearer estimate of the 
outcome to radiation administration [74]. They 
demonstrated that the dual inhibition of AKT and 
MEK increased radiosensitivity in k-RAS mutated 
non-small cell lung cancer. They also emphasi-
zed the control of DNA double strand repair by 
AKT activation might serve as a future target to 
enhance radiosensitivity. 
Several studies have dealt with the associa-
tion between abnormalities in AKT/PI3K pathway 
and its role in the pathogenesis of MPM. In a study 
conducted by Suzuki et al. in 21 MPM cell lines, 
downregulation of PTEN was most frequently 
identified as the cause for activation of AKT pa-
thway [75]. A study by Varghese et al. on the mole-
cular nature of MPM conclusively proved that ac-
tivation of PI3K and mTOR resulted in shortened 
survival in patients with MPM [76]. Zhou et al. 
demonstrated that the PI3K/AKT/mTOR pathway 
is a crucial cascade downstream of multiple acti-
vated receptor tyrosine kinases (RTK) suggesting 
the future potential of multi-point targeting of 
PI3K/mTOR as a therapeutic consideration in 
mesothelioma. Dual targeting of PI3K/mTOR by 
BEZ235 had a more significant effect on MPM 
inhibition compared to individual inhibition [77]. 
AKT kinase interacting protein (Aki1) is a scaffold 
protein for the PI3K–PDK1–AKT module. A study 
by Yamada et al. in cell-based assays showed that 
Aki1 silencing affected the CREB pathway and led 
to decreased cell viability in MPM tumors [78].
Programmed death-ligand 1 (PD-L1) 
Programmed cell death receptor 1 (PD-1) is 
expressed on activated T cells and with its li-
gands PD-L1 and PDL2, it controls T-cell effector 
functions [79]. Several studies have demonstrated 
that PD-L1 overexpression is noted in around 
30–40% of MPM patients, with a relatively gre-
ater incidence in non-epithelioid subtypes [80]. 
Moreover, MPM with PD-L1 positivity has signi-
ficantly been associated with a poorer prognosis 
than PD-L1 negative MPM (median survival of 
4.8–5.0 months vs 14.5-16.3 months) [81, 82]. 
This finding led to the consideration that immu-
ne checkpoint inhibitors which affect PD-L1 can 
provide benefit in MPM.
Pembrolizumab, a humanized monoclonal 
antibody against PD-1, with a favorable safety 
profile and strong anti-tumor activity, has been 
approved for use in the management of several 
malignancies in more than 50 countries [83]. One 
of the first studies which involved pembrolizu-
mab in MPM was the Keynote-028 Phase I trial 
conducted in 25 patients, and it showed a disease 
control rate (DCR) of 72%, a response rate of 20%, 
a median response duration of 12 months and 
was well tolerated [84]. Single arm phase II trials 
involving nivolumab, which also has PD-1 action 
showed objective response rates (ORR) between 
15–29% and a median progression free survival 
(mPFS) between 2.6–6.1 months [85, 86]. Another 
agent avelumab, which has PD-L1 blocking ac-
tivity, had a response rate of 9.4% in a study of 
53 patients [87]. The CONFIRM trial, involving 
336 patients with MPM randomized to nivolumab 
or placebo, which is ongoing in the UK hopefully 
will shed more light on this aspect [88].
Cytotoxic T lymphocyte-associated 
antigen (CTLA-4) 
CTLA-4, an inhibitory receptor located on T 
lymphocytes, binds competitively to CD80 and 
CD86 ligands and attenuates CD28-mediated 
T cell activation. By inhibiting CTLA-4, there 
can be an increase in T cell activation which 
aids in mounting stronger anti-tumor immu-
ne responses. Ipilimumab and tremelimumab 
belong to the CTLA-4 family and have shown 
significant benefit in patients with advanced 
malignancies [89, 90].  Retrospective analysis of 
the phase II MESOT-TREM-2008 study revealed 
that the dosage of tremelimumab (15 mg/kg every 
90 days) in chemotherapy-resistant advanced 
MPM was low [91]. This was followed by the 
MESOT-TREM-2012 trial with an increased do-
sage of tremelimumab (10 mg/kg every 4 weeks, 
and after 6 cycles every 12 weeks). Compared to 
1 patient who achieved partial response in the 
2008 study, 11 patients achieved disease control 
in the 2012 study [92]. Following the success of 
these 2 studies, the DETERMINE trial was con-
ducted, a randomized controlled trial involving 
571 patients who were randomized to treme-
limumab or placebo arm. However, this study 
showed that tremelimumab did not significantly 
prolong survival or improve response in patients 
with previously treated MM [93].
Advances in Respiratory Medicine 2020, vol. 88, no. 4, pages 1–9
6 www.journals.viamedica.pl
A combination therapy of PD-L1 and 
CTLA-4 checkpoint inhibitors has also been 
studied with the aim to look for a more effec-
tive response in MPM patients. The MAPS-II 
trial, which included 125 patients with relapsed 
MPM across 21 hospitals in France, compared 
nivolumab (anti-PD1) with nivolumab plus ipili-
mumab (anti-CTLA4). It was concluded at the end 
of the study that nivolumab with or without ipi-
limumab showed an equally meaningful clinical 
response but higher drug-related adverse events 
where noted in the combination group (93% 
in combination vs 89% in monotherapy) [94]. 
A combination of tremelimumab and durvalumab 
in the NIBIT trial conducted in 40 patients with 
MPM showed comparable results to the MAPS-II 
trial [95].  The INITIATE trial, a single-arm phase 
II trial in 36 eligible patients with recurrent MPM, 
studied the combination of ipilimumab with ni-
volumab. A response rate of 38% and a DCR of 
68% was noted at the study conclusion, but 94% 
reported experiencing an adverse event [96]. 
Dendritic cell (DC) therapy
DCs have often been referred to as “nature’s 
adjuvants” owing to the important role they 
carry out in initiating an immune response by 
capturing antigens and efficiently presenting 
them to lymphoid T cells. DCs also modulate 
humoral immunity by directly interacting with 
B cells and indirectly with CD4+ T helper cells 
[98]. Over the last decade, DCs have become an 
integral target in cancer immunotherapy. A study 
by Cornelissen et al. in 10 patients with MPM, 
DCs were administered with cyclophosphamide 
showed a promising overall mean survival of 
37 months (98). A recently performed clinical trial 
in which 9 patients with MPM were administered 
DCs pulsed with allogenic tumor lysate, 2 patients 
showed a partial response and a median OS hi-
gher than 22.8 months in all the patients [99].
Conclusion
MPM is an aggressive cancer of the pleural 
lining and continues to present challenges in its 
management. Radioresistance of the tumor cells 
as well as increasing resistance to chemothera-
peutic agents, have made the achievement of opti-
mal response rates difficult. A better understan-
ding of the various cell survival and pro-apoptotic 
signal pathways might open up new avenues 
in the treatment of MPM. Employing inhibitors 
targeting EGFR, ERK, CREB and AKT pathways, 
in combination with radiotherapy, might help in 
overcoming the radiation resistance developed 
by tumor cells after administration of RT. Novel 
combinations of such small molecule inhibitors 
with existing approved chemotherapy regimens 
for MPM is also another possible alternative. 
Treatment options might also be available in the 
future in the domain of immunotherapy with 
several recent studies on inhibitors of PD-L1, 
CTLA-4 and dendritic cells showing promising 
results. There is a need to continue making efforts 
to further substantiate and deepen the understan-
ding of the molecular mechanisms involved in 
MPM and to conduct clinical trials with the goal 
of optimizing treatment of MPM.
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